Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer

Launched by CITY OF HOPE MEDICAL CENTER · Oct 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect something called molecular residual disease (MRD) in patients with stage II-III colorectal cancer. MRD refers to tiny traces of cancer that may remain in the body after surgery, even when no cancer is visible. By identifying patients with MRD, doctors hope to better decide who would benefit from additional treatment, like chemotherapy, which can help improve recovery and outcomes.

To be eligible for this study, participants must be adults aged 18 and older who have been diagnosed with stage II or III colorectal cancer and have had surgery to remove the cancer. They should not have any signs of cancer spreading to other parts of the body (which would be classified as stage IV). Participants will provide consent to take part in the study, and they can expect to undergo tests that look for MRD in their blood. This trial is important because it aims to create a more personalized approach to cancer treatment, potentially leading to better care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with pathologically confirmed stage II or III colorectal cancer.
• • 2. Patients who have undergone curative-intent surgery.
• • 3. Patients with no evidence of distant metastasis (stage IV).
• • 4. Patients aged 18 years or older.
• • 5. Patients who provided written informed consent.
• Exclusion Criteria:
• • 1. Patients with stage IV cancer or those receiving neoadjuvant therapy.
• • 2. Patients with non-curative resection or requiring urgent surgery.
• • 3. Patients with a follow-up period of fewer than 3 years.
• • 4. Patients with severe comorbidities or who are unable to participate in follow-up assessments.